Showing results (51-60 of 102) with videos related to
Sort By:
Pageof 11
HIV Clinical Trials|November 25, 2003
Long-term outcome of HIV-infected patients with multinucleoside-resistant genotypesOscar Gallego, Carmen d Mendoza, Pablo Labarga, et al.Antiviral Therapy|November 30, 2005
Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trialAna Barrios, Eugenia Negredo, Pere Domingo, et al.Antiviral Therapy|June 26, 2014
Progression to advanced liver fibrosis in HIV-HCV-coinfected patients and prioritization of new hepatitis C therapiesPablo Labarga, Jose V Fernández-Montero, Mariola López, et al.Liver International : Official Journal of the International Association for the Study of the Liver|June 5, 2013
Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in SpainClara Sánchez, Zulema Plaza, Eugenia Vispo, et al.Expert Opinion on Drug Safety|July 28, 2015
Dual antiviral therapy for HIV and hepatitis C - drug interactions and side effectsIsabella Esposito, Pablo Labarga, Pablo Barreiro, et al.The Journal of Antimicrobial Chemotherapy|September 29, 2011
Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patientsZulema Plaza, Vincent Soriano, Maria del Mar Gonzalez, et al.Expert Opinion on Pharmacotherapy|November 24, 2015
New hepatitis C therapies for special patient populationsVincent Soriano, Pablo Labarga, Carmen de Mendoza, et al.Expert Opinion on Pharmacotherapy|May 6, 2016
Prevention and management of treatment failure to new oral hepatitis C drugsLaura Benítez-Gutiérrez, Pablo Barreiro, Pablo Labarga, et al.Antiviral Therapy|August 5, 2008
Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2bEugenia Vispo, Pablo Barreiro, Sonia Rodriguez-Nóvoa, et al.Antiviral Therapy|June 28, 2013
Very late relapse after discontinuation of antiviral therapy for chronic hepatitis CVincent Soriano, Eugenia Vispo, Carmen de Mendoza, et al.Pageof 11